Lawrence Steinman, Director at Pasithea Therapeutics Corp. (KTTA), bought 30,000 shares at $0.43 ($13K) on 2023-06-02, disclosed to the SEC on 2023-06-06.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| ATNF | BUY | 2023-06-02 | $22K | — | Filing → |
| ATNF | BUY | 2021-12-10 | $21K | — | Filing → |
| BCAB | SELL | 2021-11-03 | $14K | — | Filing → |